These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11291380)

  • 21. Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program.
    Blomé MA; Björkman P; Flamholc L; Jacobsson H; Molnegren V; Widell A
    J Viral Hepat; 2011 Dec; 18(12):831-9. PubMed ID: 21114587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].
    Koch C; Araújo F
    Acta Med Port; 2013; 26(4):371-6. PubMed ID: 24016646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus infection and hepatitis: biosafety in radiology.
    Wall SD; Howe JM; Sawhney R
    Radiology; 1997 Dec; 205(3):619-28. PubMed ID: 9393512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients, needles, and healthcare workers: understanding the epidemiology, pathophysiology, and transmission of the human immunodeficiency virus, hepatitis B and C, and cytomegalovirus.
    Hibberd PL
    J Intraven Nurs; 1995; 18(6 Suppl):S22-31. PubMed ID: 8714928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
    Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I
    AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
    Devi KhS; Brajachand N; Singh HL; Singh YM
    J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.
    U.S. Public Health Service
    MMWR Recomm Rep; 2001 Jun; 50(RR-11):1-52. PubMed ID: 11442229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An estimation of the occupational risk of HBV, HCV and HIV infection among Indonesian health-care workers.
    Agustian D; Yusnita S; Susanto H; Sukandar H; de Schryver A; Meheus A
    Acta Med Indones; 2009 Jul; 41 Suppl 1():33-7. PubMed ID: 19920296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nosocomial hepatitis B virus, hepatitis C virus and HIV infections by infectious medial personnel].
    Hasselhorn HM; Hofmann F
    Gesundheitswesen; 1998 Oct; 60(10):545-51. PubMed ID: 9844287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. US outbreak investigations highlight the need for safe injection practices and basic infection control.
    Perz JF; Thompson ND; Schaefer MK; Patel PR
    Clin Liver Dis; 2010 Feb; 14(1):137-51; x. PubMed ID: 20123446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risk of transfusion-transmitted infections in sub-Saharan Africa.
    Jayaraman S; Chalabi Z; Perel P; Guerriero C; Roberts I
    Transfusion; 2010 Feb; 50(2):433-42. PubMed ID: 19843290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a benefit for health care workers in testing HIV, HCV and HBV in routine before elective arthroplasty?
    Winkelmann M; Sorrentino JN; Klein M; Macke C; Mommsen P; Brand S; Schröter C; Krettek C; Zeckey C
    Orthop Traumatol Surg Res; 2016 Jun; 102(4):513-6. PubMed ID: 27062330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa.
    Ekwueme DU; Weniger BG; Chen RT
    Bull World Health Organ; 2002; 80(11):859-70. PubMed ID: 12481207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASGE guideline for infection control during GI endoscopy.
    ; Calderwood AH; Day LW; Muthusamy VR; Collins J; Hambrick RD; Brock AS; Guda NM; Buscaglia JM; Petersen BT; Buttar NS; Khanna LG; Kushnir VM; Repaka A; Villa NA; Eisen GM
    Gastrointest Endosc; 2018 May; 87(5):1167-1179. PubMed ID: 29573782
    [No Abstract]   [Full Text] [Related]  

  • 35. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003.
    Soldan K; Davison K; Dow B
    Euro Surveill; 2005 Feb; 10(2):17-9. PubMed ID: 15735312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses.
    Kermode M
    Health Promot Int; 2004 Mar; 19(1):95-103. PubMed ID: 14976177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of infection in health care workers following occupational exposure to a noninfectious or unknown source.
    Kuruuzum Z; Yapar N; Avkan-Oguz V; Aslan H; Ozbek OA; Cakir N; Yuce A
    Am J Infect Control; 2008 Dec; 36(10):e27-31. PubMed ID: 19084160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occupational blood-borne diseases in surgery.
    Fry DE
    Am J Surg; 2005 Aug; 190(2):249-54. PubMed ID: 16023440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing.
    Offergeld R; Faensen D; Ritter S; Hamouda O
    Euro Surveill; 2005 Feb; 10(2):8-11. PubMed ID: 15735310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.